For customers looking to accelerate their CRISPR gene editing program from discovery to clinical trials, our Engineering Run and full cGMP Compliant gRNA Manufacturing Services offer a streamlined and regulated solution. Backed by comprehensive documentation, our guide RNA CRISPR services simplify regulatory filings, offering a straightforward path to clinical success.
Lab to life changing advances. We'll help.
Leverage advanced CRISPR technology to empower and streamline approaches to genome research. Ensure regulatory compliance through our specialized cGMP guide RNA manufacturing services, designed to support gene editing projects. This commitment to the highest standards ensures Guide RNA products enhance efficiency of CRISPR genome editing projects through the therapeutic development approval process. Bring your genomic research to the forefront of personalized medicine innovation. Request a consultation today.
Through access to IDT tools and services you will benefit from our:
Start the conversation today to explore how our cGMP manufacturing service can accelerate your CRISPR therapeutics project. Click on "request a consultation" to provide brief information about your project, and we'll be in touch to discuss it ASAP.
IDT’s guide RNAs produced at its Therapeutic Oligonucleotide Manufacturing Facility deliver the high-quality current Good Manufacturing Practices (cGMP) material required for successful completion of your preclinical studies and clinical trials.
Engineering run: Synthetic guide RNA produced by the same manufacturing process as cGMP products but with limited Quality Assurance documentation.
cGMP: Synthetic guide RNA manufactured under cGMP-certified conditions and includes full Quality Assurance Documentation.
Engineering Run | cGMP | |
---|---|---|
Availability | Delivery times after placing the order | Delivery times after placing the order |
Cleanroom | Certification not required | ISO 8 Clean Room – Certified |
Changeover | In-place with cleaning validation | In-place with cleaning validation |
Materials | QA release on raw materials | QA release on raw materials |
Batch Records | Draft based on customer’s specifications | Based on customer specification |
Release Testing | Qualified methods | Validated methods |
Through comprehensive quality control and analytical testing, we are committed to ensure that our therapeutic oligonucleotides consistently meet the regulatory requirements to accelerate your project and bring your discoveries to life.
Category | Attribute | Method |
---|---|---|
Identity | Molecular Weight | ESI-MS |
Purity | Purity | Single-channel CE |
Process Related Impurities | Elemental Impurities | USP <233> |
Residual Solvents | USP <467> | |
Safety | Endotoxin | USP <85> limulus amebocyte lysate (LAL) |
Bioburden | USP <61/62> | |
Yield | UV/Vis | Optical Density at 260nm |
General | Appearance | Visual Inspection |
The functional performance of 100 nt Cas9 sgRNAs targeting HPRT1 was studied using a cell-based editing activity assay in K562 cells (a human leukemia cell line) and an in vitro cleavage assay. As shown in Figure 1, pilot-run gRNAs performed better than the guide RNAs with the same sequence but purified using the standard desalt method. However, similar in-cellulo % editing and in vitro % cleavage performance were observed with pilot runs and HPLC-purified guide RNAs. Moreover, different pilot runs exhibited similar functional activity, demonstrating batch-to-batch consistency.
Figure 1. Functional performance of 100 nt Cas9 sgRNAs targeting HPRT1 when used in K562 CRISPR editing and in vitro DNA cleavage experiments. CRISPR editing outcomes were assessed via NGS using the rhAmpSeq™ CRISPR Analysis System following electroporation (Lonza) into K562 cells. Cas9-mediated DNA cleavage in vitro was assessed using the Fragment Analyzer system. (n = 3, error bars represent standard deviation. RUO controls were purified using either HPLC or standard desalt methods).
This data is generated from pilot runs on equivalent Q7 equipment using representative Q7 manufacturing processes, methods, and tests.
The ICH Q7 standard IDT used to manufacture cGMP guide RNA can allow these molecules to be used as active pharmaceutical ingredients under specific conditions. The level of change control, validation/verification, record keeping, quality control, and so on is more stringent for this service than for IDT’s research use only (RUO) products.
IDT’s RUO products are manufactured under ISO 9001:2015 conditions to ensure a high-level of quality suitable for research applications.Research use only (RUO), Engineering run and cGMP guide RNAs are available from 20 nt up to 150 nt, at yields ranging from 100 mg up to grams. Custom development options are also available for additional length ranges, modifications, base types, and formulations. Contact us for a consultation to review your project’s needs.
IDT offers a comprehensive QC and analytical testing package including identity, purity, yield, endotoxin, bioburden testing, and physical attributes. In addition to standard release testing, IDT will evaluate supporting additional testing on a case-by-case basis. Contact us to discuss your testing requirements.
IDT is prepared to support you with required information based on use, clinical program phase and modality. These include but are not limited to drug master files, site master files, site audits, and so on. Contact us for a consultation to discuss your regulatory needs.
cGMP23-2627_002
cGMP gRNA products are manufactured in accordance with ICH Q7. IDT engineering runs and cGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established. This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations.